Osborne CK - Search Results

1

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.

Schettini F, Pascual T, Conte B, Chic N, Brasó-Maristany F, Galván P, Martínez O, Adamo B, Vidal M, Muñoz M, Fernández-Martinez A, Rognoni C, Griguolo G, Guarneri V, Conte PF, Locci M, Brase JC, Gonzalez-Farre B, Villagrasa P, De Placido S, Schiff R, Veeraraghavan J, Rimawi MF, Osborne CK, Pernas S, Perou CM, Carey LA, Prat A. Schettini F, et al. Among authors: osborne ck. Cancer Treat Rev. 2020 Mar;84:101965. doi: 10.1016/j.ctrv.2020.101965. Epub 2020 Jan 17. Cancer Treat Rev. 2020. PMID: 32000054 Free PMC article.

2

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.

Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK. Benz CC, et al. Among authors: osborne ck. Breast Cancer Res Treat. 1992;24(2):85-95. doi: 10.1007/BF01961241. Breast Cancer Res Treat. 1992. PMID: 8095168

3

Time-dependence of hazard ratios for prognostic factors in primary breast cancer.

Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Hilsenbeck SG, et al. Among authors: osborne ck. Breast Cancer Res Treat. 1998;52(1-3):227-37. doi: 10.1023/a:1006133418245. Breast Cancer Res Treat. 1998. PMID: 10066085

4

Steroid hormone receptors in breast cancer management.

Osborne CK. Osborne CK. Breast Cancer Res Treat. 1998;51(3):227-38. doi: 10.1023/a:1006132427948. Breast Cancer Res Treat. 1998. PMID: 10068081 Review.

5

Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.

Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK, Osborne CK, Fuqua SA. Hilsenbeck SG, et al. Among authors: osborne ck. J Natl Cancer Inst. 1999 Mar 3;91(5):453-9. doi: 10.1093/jnci/91.5.453. J Natl Cancer Inst. 1999. PMID: 10070945

6

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.

Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Schiff R, et al. Among authors: osborne ck. J Natl Cancer Inst. 2000 Dec 6;92(23):1926-34. doi: 10.1093/jnci/92.23.1926. J Natl Cancer Inst. 2000. PMID: 11106684

7

Estrogen receptor: current understanding of its activation and modulation.

Osborne CK, Schiff R, Fuqua SA, Shou J. Osborne CK, et al. Clin Cancer Res. 2001 Dec;7(12 Suppl):4338s-4342s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916222 Review.

8

Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.

Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Liu Y, et al. Among authors: osborne ck. Oncogene. 2002 Oct 31;21(50):7680-9. doi: 10.1038/sj.onc.1205883. Oncogene. 2002. PMID: 12400010

9

Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

Schiff R, Massarweh S, Shou J, Osborne CK. Schiff R, et al. Among authors: osborne ck. Clin Cancer Res. 2003 Jan;9(1 Pt 2):447S-54S. Clin Cancer Res. 2003. PMID: 12538499 Review.

10

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Osborne CK, et al. J Natl Cancer Inst. 2003 Mar 5;95(5):353-61. doi: 10.1093/jnci/95.5.353. J Natl Cancer Inst. 2003. PMID: 12618500

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

372 results

Search Page